ADA and cancer: The lack of ADA reactivity with zolbetuximab in this study is consistent with the absence of ADA reactivity in G/GEJ cancer patients receiving a single dose of zolbetuximab over the dose range of 33–1000 mg/m2 in a phase 1 study (Sahin et al. 2018) or biweekly zolbetuximab at doses ranging from 1300 to 3600 mg/m2 in the phase 2a MONO study (Tureci et al. 2019b).